Research: Why commercialization of gene therapy stalled

It has been 40 years since recombinant technologies first enabled consideration of gene therapy for human disease, and 30 years since the first gene therapy companies were formed. Yet, there are no gene therapies on the market in the US or EU. A recent research paper from the Center for Integration of Science and Industry explores how asynchrony between capital investments and the maturation of gene therapy technologies may have contributed to this delay.

Sticky Post: